Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05190172
Other study ID # 265626
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 14, 2022
Est. completion date December 31, 2041

Study information

Verified date April 2024
Source Oslo University Hospital
Contact Petter Brandal, MD PhD
Phone +47 22934000
Email petter.brandal@ous-hf.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Proton therapy is a powerful tool enabling oncologists to spare normal tissue around the target for irradiation much better than what can be achieved with photon irradiation. The infiltrative nature of IDH-mutated grade II and III diffuse glioma, however, renders proton therapy a potential problem. A randomized controlled trial (RCT) is the only option when trying to ensure that chances of long-term survival are not impaired seeking to reduce unwanted late treatment effects. Non-inferiority of proton therapy compared to photon irradiation is the primary endpoint of the RCT. Hence, PRO-GLIO has two main objectives. First, PRO-GLIO will evaluate if proton therapy is safe in patients with IDH-mutated grade II and III diffuse glioma, showing that survival figures at 2 years from radiotherapy are not poorer in the proton arm than in the photon arm. Second, we want to find the true number of patients in need of rehabilitation in both arms, and evaluate if proton therapy conveys a higher QoL than photon irradiation at 2 years from radiotherapy.


Description:

PRO-GLIO aims at establishing proton irradiation as standard radiotherapy for IDH-positive diffuse glioma grade II and III patients. First, PRO-GLIO will show that proton therapy is safe, despite the infiltrative nature of these tumors. Second, the HRQOL and neuropsychological investigating part of PRO-GLIO will show that patients irradiated with protons have a better outcome in this regard than those irradiated with photons. Inclusion criteria are a diagnosis of grade II or grade III IDH-mutated diffuse glioma, good performance status, indication for radiotherapy and age between 18 and 65 years. Patients will be randomized to proton or photon radiotherapy and the study work will be divided in three work packages (WP). 1. In WP1, survival data will be the main focus, but the estimation of QALY will also be an important part - concentrating on differences between the two study arms. If there is truly no difference between the proton and photon radiotherapy on the probability of FIFS after two years, then 224 randomized patients (112 in each treatment group) are required to be 80% certain that the upper limit of a two-sided 95% confidence interval will exclude a difference in favor of the photon radiotherapy of more than 15%. This assumes a 0.8 probability of FIFS in the control arm, and no drop-outs. 2. In WP2, a battery of validated neuropsychological tests will be used to test the cognive abilities of the patients. All patients will be testes using an internet-based test (Cog-State) and 1/3 of patients will also have an in-depth neuropsychological evaluation. The two methods will be compared. 3. In WP3, a battery of patient-reported outcome measures (PROMS) questionnaires will be used to establish which subjective challenges this patient group struggles the most with.


Recruitment information / eligibility

Status Recruiting
Enrollment 225
Est. completion date December 31, 2041
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Patients must be 18 to 65 years old at the day of consenting 2. IDH-mutated astrocytoma grade II or III, or oligodendroglioma grade II or III according to WHO 2016 3. Indication for radiotherapy 4. WHO/ECOG performance status 0-2 5. Ability to undergo MRI 6. No significant contrast enhancing tumor at the time of randomization. In recurrence patients, no contrast enhancement is allowed unless a new biopsy confirms the diagnosis of IDH-mutated astrocytoma grade 2 or 3, or oligodendroglioma grade 2 or 3. 7. Ability and willingness to travel to The Skandion Clinic for proton therapy if randomized to the proton therapy arm 8. Women of child-bearing potential (WOCBP) must agree to use an effective method of contraception during radiotherapy, chemotherapy and 1 year after completion of chemotherapy. Pregnancy is not an ineligibility criterium if radiotherapy is indicated and cannot be postponed 9. Ability to understand the information about the study and included treatment and give a written informed consent 10. Signed informed consent 11. Ability to speak and understand Norwegian or Swedish language Exclusion Criteria: 1. Prior treatment (except surgery) for diffuse glioma 2. Concomitant or previous malignancies. Exceptions are adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix uteri with a follow-up time of at least 3 years, or other previous malignancy with a disease-free interval of at least 5 years 3. More than 2 months from randomization to start radiotherapy 4. Known CDKN2A/B homozygous deletion 5. Presence of any medical, psychological, familial, sociological, or geographical characteristic that might impair patient compliance for study protocol procedures including follow-up 6. Body weight > 150 kg

Study Design


Intervention

Radiation:
Radiation therapy
Radiation therapy either with protons or photons

Locations

Country Name City State
Norway Oslo University Hospital Oslo

Sponsors (12)

Lead Sponsor Collaborator
Oslo University Hospital Haukeland University Hospital, Karolinska University Hospital, Lund University Hospital, Ôrebro University Hospital, Sahlgrenska University Hospital, Sweden, St. Olavs Hospital, The Skandion Clinic, University Hospital of North Norway, University Hospital, Linkoeping, University Hospital, Umeå, Uppsala University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary First intervention free survival (FIFS) at 2 years Survival 2 years
Secondary Total fatigue score assessed by the fatigue questionnaire developed by T. Chalder et al. Symptom 2, 5, 10 and 15 years
Secondary Change in cognitive functioning (composite score from CANTAB-tests) at 2 years Objective examination 5 months and 2, 5, 10 and 15 years
Secondary Overall survival Survival Median and at 2, 5, 10 and 15 years
Secondary FIFS Survival Median, 5, 10 and 15 years
Secondary Progression-free survival Survival Median and at 2, 5, 10 and 15 years
Secondary Change in neurological function as assessed by the NANO scale Objective examination 2, 5, 10 and 15 years
Secondary Global cognitive impairment index Neuropsychological endpoint 2, 5, 10 and 15 years
Secondary Rate of local, distant and combined recurrences Disease development 2, 5, 10 and 15 years
Secondary Rate of patients without epileptic seizures Symptom 5 months and 2, 5, 10 and 15 years
Secondary EORTC QLQ C30-based algorithm score Quality of life 2, 5, 10 and 15 years
Secondary Incremental cost effectiveness ratio Health economics 2, 5, 10 and 15 years
Secondary Rate of adverse events Toxicity At 6 weeks, 3 and 5 months and 1 year, 2 , 5, 10 and 15 years
Secondary Costs in Norwegian kroner related to loss of production caused by disease and treatment Health economics 2, 5, 10 and 15 years
See also
  Status Clinical Trial Phase
Terminated NCT02764151 - First in Patient Study for PF-06840003 in Malignant Gliomas Phase 1
Recruiting NCT04843085 - Proteomic Characterization of Aggressive Oligodendrogliomas
Completed NCT02903784 - Neural Basis of Language Processing N/A
Completed NCT00165360 - Prolonged Daily Temozolomide for Low-Grade Glioma Phase 2
Recruiting NCT04541082 - Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Phase 1
Completed NCT02530320 - Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Phase 2
Terminated NCT00389090 - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Phase 2
Active, not recruiting NCT02549833 - Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma Phase 1
Recruiting NCT06038760 - Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Recruiting NCT05624736 - Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Recruiting NCT05345002 - All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma Phase 2
Completed NCT03900689 - Social Determinants of Health in Glioblastoma Population
Completed NCT02747407 - Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Recruiting NCT04970615 - Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated NCT01836549 - Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Phase 2
Recruiting NCT03796273 - Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Early Phase 1
Terminated NCT00031538 - Genetic Analysis of Brain Tumors
Completed NCT01609790 - Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Phase 2
Not yet recruiting NCT05513859 - Investigational Imaging Technique During Brain Surgery N/A